Cerus (NASDAQ:CERS) Director Eric Bjerkholt Sells 20,454 Shares of Stock

Cerus Corporation (NASDAQ:CERS) Director Eric Bjerkholt sold 20,454 shares of the stock in a transaction that occurred on Tuesday, June 9th. The shares were sold at an average price of $2.60, for a total value of $53,180.40. Following the completion of the sale, the director directly owned 261,679 shares of the company’s stock, valued at approximately $680,365.40. This represents a 7.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Cerus Price Performance

NASDAQ:CERS opened at $2.59 on Friday. Cerus Corporation has a one year low of $1.15 and a one year high of $3.15. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.06 and a current ratio of 1.63. The stock has a market cap of $518.96 million, a PE ratio of -51.80 and a beta of 1.77. The stock has a 50 day moving average price of $2.34 and a 200 day moving average price of $2.20.

Cerus (NASDAQ:CERS) last posted its earnings results on Thursday, April 30th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.03) by $0.02. The company had revenue of $59.89 million during the quarter, compared to analysts’ expectations of $55.68 million. Cerus had a negative return on equity of 15.18% and a negative net margin of 4.41%. Equities research analysts expect that Cerus Corporation will post -0.02 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Wall Street Zen raised Cerus from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Cerus in a research note on Wednesday, March 25th. BTIG Research raised Cerus from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research note on Friday, May 1st. Finally, Zacks Research raised Cerus from a “strong sell” rating to a “hold” rating in a research note on Thursday, April 30th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Cerus currently has an average rating of “Hold” and a consensus target price of $4.00.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Cibc World Markets Corp purchased a new stake in Cerus during the 4th quarter worth about $25,000. CIBC Bancorp USA Inc. purchased a new stake in Cerus during the 3rd quarter worth about $31,000. Dynamic Technology Lab Private Ltd purchased a new stake in Cerus during the 1st quarter worth about $32,000. Y Intercept Hong Kong Ltd purchased a new stake in Cerus during the 1st quarter worth about $35,000. Finally, Aquatic Capital Management LLC purchased a new stake in Cerus during the 3rd quarter worth about $35,000. 78.37% of the stock is currently owned by hedge funds and other institutional investors.

About Cerus

Cerus Corporation is a biomedical products company dedicated to enhancing the safety of blood transfusions worldwide. Its flagship offering, the INTERCEPT Blood System, employs pathogen reduction technology designed to inactivate a broad spectrum of viruses, bacteria, and parasites in donated platelets and plasma. This approach aims to mitigate the risk of transfusion-transmitted infections and improve blood component safety for patients.

The INTERCEPT platform integrates seamlessly into existing blood center workflows, providing a one-step treatment process for collected blood products.